The DOI matches its OpenAlex record; 17 of the 17 references it cites were found in a registry or an index.
Prognostic Factors for Malignant Transformation in Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma
Abstract
PURPOSE: To evaluate the natural history of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM), identify early predictors of evolution, and assess whether associated conditions correlate with disease progression. PATIENTS AND METHODS: A total of 1,231 consecutive patients with either MGUS (n = 1,104) or SMM (n = 127) diagnosed from July 1975 to March 1998 were included in the study. Cumulative survival probability and cumulative probability of transformation into lymphoproliferative disease were calculated by means of the Kaplan-Meier estimator. Univariate and multivariate Cox models were used to identify possible predictors of malignant evolution. RESULTS: Cumulative transformation probability at 10 and 15 years was 14% and 30%, respectively. At a median follow-up of 65 months (range, 12 to 239 months), 64 MGUS cases (5.8%) evolved to multiple myeloma (MM) (n = 43), extramedullary plasmacytoma (n = 1), primary amyloidosis (n = 1), Waldenström's macroglobulinemia (n = 12), non-Hodgkin's lymphoma (n = 6), and B-chronic lymphocytic leukemia (n = 1). At a median follow-up of 72 months (range, 12 to 247 months), 25 SMMs (19.7%) evolved to overt MM. A lower evolution risk was observed in MGUS than in SMM (P <.0001). Greater than 5% marrow plasmacytosis, detectable Bence Jones proteinuria, polyclonal serum immunoglobulin reduction, and high erythrocyte sedimentation rate (ESR) were independent factors influencing MGUS transformation. SMM progression correlated with greater than 10% marrow plasma cells, detectable Bence Jones proteinuria, and immunoglobulin (Ig) A isotype. Neither concomitant diseases nor immunosuppression correlated with progression. CONCLUSION: Careful evaluation of marrow plasmacytosis, urinary paraprotein, background immunoglobulins, ESR, and paraprotein isotype might help identify at presentation patients with benign monoclonal gammopathies requiring stricter monitoring.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Primary systemic amyloidosis: clinical and laboratory features in 474 cases.
Kyle, R. A., & Ma, G. (1995) · PubMed · Cited by 1,255
Monoclonal gammopathy of undetermined significance
Kyle, R. A. (1978) · The American Journal of Medicine · doi:10.1016/0002-9343(78)90522-3 · Cited by 607
Kyle, R. A., & Greipp, P. R. (1980) · New England Journal of Medicine · doi:10.1056/nejm198006123022405 · Cited by 452
Frequency of Pathological Proteins (M‐components) in 6,995 Sera from an Adult Population
AXELSSON, U., BACHMANN, R., & HÄLLÉN, J. (1966) · Acta Medica Scandinavica · doi:10.1111/j.0954-6820.1966.tb05453.x · Cited by 436
Murphy, S., Peterson, P., Iland, H., & Laszlo, J. (1997) · PubMed · Cited by 404
“Benign” Monoclonal Gammopathy—After 20 to 35 Years of Follow-Up
KYLE, R. A. (1993) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(12)60015-9 · Cited by 338
Staging and kinetics of multiple myeloma.
Durie, B. G. M. (1986) · PubMed · Cited by 212
'Benign' monoclonal gammopathy. A misnomer?
Kyle, R. A. (1984) · JAMA · doi:10.1001/jama.251.14.1849 · Cited by 153
Malignant transformation and life expectancy in monoclonal gammopathy of undetermined significance
Bladé, J., López‐Guillermo, A., Rozmán, C., Cervantes, F., Salgado, C., Aguilar, J., Corrons, J. V., & Montserrat, E. (1992) · British Journal of Haematology · doi:10.1111/j.1365-2141.1992.tb08245.x · Cited by 151
Evaluation of monoclonal gammopathies in the “well” elderly
Crawford, J., Eye, M. K., & Cohen, H. J. (1987) · The American Journal of Medicine · doi:10.1016/0002-9343(87)90375-5 · Cited by 134
Cited by
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
Rajkumar, S. V., Dimopoulos, M. A., Palumbo, A., Blade, J., Merlini, G., Mateos, M.-V., Kumar, S., Hillengass, J., Kastritis, E., Richardson, P., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70442-5 · Cited by 4,978
The International Myeloma Working Group (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04355.x · Cited by 2,321
Clinical Course and Prognosis of Smoldering (Asymptomatic) Multiple Myeloma
Kyle, R. A., Remstein, E. D., Therneau, T. M., Dispenzieri, A., Kurtin, P. J., Hodnefield, J. M., Larson, D. R., Plevak, M. F., Jelinek, D. F., Fonseca, R., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070389 · Cited by 921
Kyle, R. A., Durie, B. G. M., Rajkumar, S. V., Landgren, O., Blade, J., Merlini, G., Kröger, N., Einsele, H., Vesole, D. H., Dimopoulos, M., et al. (2010) · Leukemia · doi:10.1038/leu.2010.60 · Cited by 888
Rajkumar, S. V., Kyle, R. A., Therneau, T. M., Melton, L. J., Bradwell, A. R., Clark, R. J., Larson, D. R., Plevak, M. F., Dispenzieri, A., & Katzmann, J. A. (2005) · Blood · doi:10.1182/blood-2005-03-1038 · Cited by 702
Metadata
- Authors
- Cesana, C., Klersy, C., Barbarano, L., Nosari, A., Crugnola, M., Pungolino, E. M., Gargantini, L., Granata, S., Valentini, M., & Morra, E.
- Venue
- Journal of Clinical Oncology
- Publisher
- Lippincott Williams & Wilkins
- Published
- 2002-03-15
- Volume
- 20
- Issue
- 6
- Pages
- 1625-1634
- ISSN
- 0732-183X (ISSN-L)
- OpenAlex
- W2075092656
- Cited by
- 259
- References
- 17
- FWCI
- 4.91
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prognostic Factors for Malignant Transformation in Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma. https://app.cochat.ai/papers/10.1200/jco.20.6.1625
- The paper
- Cesana, C., Klersy, C., Barbarano, L., Nosari, A., Crugnola, M., Pungolino, E. M., Gargantini, L., Granata, S., Valentini, M., & Morra, E. (2002). Prognostic Factors for Malignant Transformation in Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma. Journal of Clinical Oncology. https://doi.org/10.1200/jco.20.6.1625
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.